Epidermolysis Bullosa Market is Anticipated to Witness High Growth Owing to Rising Government Initiatives


 Epidermolysis bullosa (EB) is a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes. The major symptoms of EB include blistering, scarring, and disfigurement of skin. There are different types of EB varying in severity, with some cases being life-threatening. The treatment of EB includes proper wound-care to prevent infection and pain management. While there is no complete cure for EB, gene therapy and stem cell therapy offer promising treatment options. The increasing prevalence of EB across the globe and growing awareness regarding its treatment methods are fueling the demand for EB therapies.


The Global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the epidermolysis bullosa are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma plc holds a major market share due to its advanced gene-therapy portfolio.

There is a high unmet need for safer and more efficacious treatment options for EB patients. Companies are investing heavily in R&D to develop gene therapies and stem cell therapies for EB. Emerging treatment options like fibroblast therapies and topical biomimetic engineered skin grafts also provide significant opportunities in the EB market.

North America dominates the global EB market, followed by Europe. However, the Asia Pacific region is anticipated to witness the highest growth during the forecast period due to growing incidences of EB. The increasing focus of market players and research institutes on developing novel therapies will support the market expansion globally.

Market Drivers
The rising government initiatives towards rare disease treatment is a major market driver. The governments of various countries are raising awareness about EB, its treatment, and providing financial assistance to patients. This is increasing the adoption of advanced treatment options.

Growing healthcare expenditure is also fueling the market growth. With rising disposable incomes, people can afford high-cost EB therapies. The increasing sponsorship of clinical trials by pharmaceutical companies and research institutes is additionally supporting the market expansion.

Market Restrain
However, the market growth can be restrained by the high cost of advanced EB treatment options such as gene and stem cell therapies. Since EB is a rare disease, the low patient pool also hampers market revenues. Lengthy regulatory approvals and the complexity of gene and cell therapy development further challenge the market to a certain extent.

Segment Analysis
This market can be segmented into dystrophic epidermolysis bullosa (DEB)and junctional epidermolysis bullosa (JEB). The dystrophic epidermolysis bullosa (DEB) segment is dominating currently due to higher prevalence of DEB as compared to other forms. DEB accounts for majority share of around 50% of total EB cases.

Regional Analysis
North America region is currently dominating the epidermolysis bullosa market owing to developed healthcare infrastructure, increasing research funding and growing patient awareness regarding new treatment options in countries like US and Canada. The Asia Pacific region is expected to witness fastest growth over the forecast period due to growing geriatric population, increasing healthcare expenditure and developing pharmaceutical industry.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more